The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 06, 2025

Filed:

Jan. 16, 2024
Applicant:

Brosmed Medical Co., Ltd., Guangdong, CN;

Inventors:

Liwei Wang, Guangdong, CN;

Junyi Huang, Guangdong, CN;

Zhijun Zhang, Guangdong, CN;

Bin Li, Guangdong, CN;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61L 29/16 (2005.12); A61L 29/04 (2005.12); A61L 29/08 (2005.12);
U.S. Cl.
CPC ...
A61L 29/16 (2012.12); A61L 29/049 (2012.12); A61L 29/085 (2012.12); A61L 2300/216 (2012.12); A61L 2300/416 (2012.12); A61L 2300/602 (2012.12); A61L 2300/608 (2012.12); A61L 2300/62 (2012.12); A61L 2420/02 (2012.12); A61L 2420/06 (2012.12);
Abstract

A drug coated balloon includes a balloon body and a drug loaded coating layer. The drug loaded coating layer includes a first drug loaded coating component having at least two controllable sustained release drugs with different drug release kinetics, and a second drug loaded coating component including an active drug. The second drug loaded coating component is dispersed among the controllable sustained release drugs and couples the controllable sustained release drugs on the balloon body. The first and second drug loaded coating components are both non-hydrophilic compositions. The drug coated balloon provides sufficient initial drug loading dosage to the lesion site, and has adjustable drug release rate, thereby allowing the drug coated balloon to provide bioactive drugs to the treatment site at different stages of the cascade reaction of vascular restenosis, providing the controllable long-acting therapeutic drugs, and improving the overall vascular drug release efficacy.


Find Patent Forward Citations

Loading…